Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseobservationalRules rewrite
Not a traditional drug phase: testing Disease-Modifying Therapy for Alzheimer's Disease (AD)
The goal of this multicenter retrospective watch-and-measure (no experimental treatment required) study is to learn about the real-world safety and clinical effectiveness of disease-modifying therapy (DMT) in adults with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or AD dementia. The main questions it aims to answer are: What are the safety outcomes of DMT, including amyloid-related imaging abnormalities (ARIA), side effects, and infusion reactions (IRRs)?
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 3,000 people at Shanghai. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
Official title (unrewritten)
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Interventions: Disease-Modifying Therapy
Primary outcome (registry wording): Safety of Disease-Modifying Therapy
Who it is for (from inclusion criteria)
Ages 18 Years to any
Disease-Modifying Therapy Group
Patients with a baseline diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or dementia due to AD according to the 2011 National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic criteria
Age ≥18 years at baseline
Patients who have received disease-modifying therapy (DMT)
Alzheimer's disease-related amyloid pathology confirmed or supported by amyloid positron emission tomography (PET), cerebrospinal fluid (CSF) biomarkers, or blood biomarkers
Non-Disease-Modifying Therapy Group
Patients who have not received disease-modifying therapy (DMT)
Who the registry excludes
Amyloid-beta (Aβ) pathological evidence is missing or does not meet the study requirements
Presence of a major neurological disorder that may confound the assessment of cognitive outcomes
Previous treatment with other anti-amyloid monoclonal antibodies, or participation in an treatment clinical trial that may affect the assessment of study outcomes
Serious inconsistencies or errors in key participant information
The specific aims of the study are: Primary: To determine the presence and regional distribution of microglial activation, as assessed by Fluorine-18 (18F) labeled "Peripheral Benzodiazepine Receptor 06" (PBR06) -PET, in subjects with active Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), and Alzheimer's Disease (AD) as compared to healthy controls Secondary: 1. To assess the relationship between microglial activation and clinical variables including disease severity and comorbidities (such as pain, fatigue and/or depression), as well as clinical MRI findings (such as lesions and atrophy) 2.
This study will look at whether nabilone is an effective treatment for agitation in Alzheimer's disease (AD) patients. Agitation is highly prevalent in patients with AD and is one of the most distressing and challenging-to-treat symptoms.
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07923812?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07923812?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.